Login to Your Account

Other News To Note

Friday, August 5, 2011
Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, reported results from a preclinical study that the companies said provided evidence that MDV3100, an oral androgen receptor antagonist in clinical development to treat advanced prostate cancer patients, inhibits proliferation of breast cancer cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription